Washington Takes Aim at Chinese Biotech — And Korea Is Watching Closely

So here's something that flew a bit under the radar this week but could have major implications for Korea's pharmaceutical industry. A senior U.S. congressman has written a formal letter urging the Treasury Department to block American capital from flowing into Chinese biotech companies — and the Korean biopharma sector is paying very close attention.

Representative John Moolenaar, the chairman of the House Select Committee on China, sent the letter on May 21st to Treasury Secretary Scott Bessent, calling on the department to include biotechnology in the list of prohibited sectors under the COINS Act — that stands for the Comprehensive Outbound Investment National Security Act. The law is designed to stop U.S. capital from funding advanced technology development in adversarial nations, and right now the government is still working out the specific regulations.

What prompted this? Moolenaar's letter pointed specifically to a deal that raised alarm bells: Bristol Myers Squibb, one of America's biggest pharmaceutical companies, recently signed a deal worth 15 billion dollars with Chinese drugmaker Hengrui Pharmaceuticals, which included transferring intellectual property rights to China. That kind of arrangement, the argument goes, is essentially funding a competitor in a strategic industry.

"China has been pursuing a deliberate, state-directed strategy to dominate the global biotech sector," Moolenaar wrote, "including drug development, biopharmaceutical manufacturing, and clinical research capabilities."

The numbers behind this concern are striking. According to the Korea Biotechnology Industry Organization's Bio-Economy Research Center, licensing deals between multinational pharmaceutical firms and Chinese biotech companies reached roughly 136 billion dollars last year. And here's the stat that really tells the story: in 2020, Chinese companies accounted for zero percent of major global drug licensing deals worth over 50 million dollars. Last year? That figure hit 48 percent. That is a staggering shift in just five years.

What This Means for Korean Biopharma

Now, why does this matter for Korea? The Korean pharmaceutical and biotech industry has been on a roll. Last year, domestic companies recorded a record-breaking 20 trillion Korean won — roughly 14.5 billion dollars — in technology export deals. The concern is that if the U.S. starts restricting American companies from licensing Chinese drugs, the global licensing landscape will be reshuffled, and Korean companies need to know where they land.

The good news, according to analysts, is that Korea may actually benefit from this geopolitical tension. Heo Hye-min, a researcher at Kiwoom Securities, put it plainly: Korea's long track record of partnerships and its reputation for reliable data quality are genuine advantages over Chinese competitors. She expects to see a range of new technology deals in the second half of the year — not just with major pharmaceutical companies, but also with emerging biotech firms sometimes called "NewCo" structures. So while the U.S.-China biotech rivalry is tightening the playing field, Korea could find itself in a stronger position as a trusted alternative.

A New Fed Chair Steps In — Korea Feels the Ripples

Shifting gears now to a story that affects every corner of the global economy, including Korea. Kevin Warsh has officially been sworn in as the new Chair of the U.S. Federal Reserve — that's the American central bank, whose decisions on interest rates ripple through currency markets, bond yields, and capital flows worldwide. For Korea, that means the won-dollar exchange rate, foreign investment inflows, and even household debt levels are all indirectly shaped by what happens in Washington.

Warsh took his oath of office on May 22nd, was elected chair of the Federal Open Market Committee — the body that sets interest rates — and delivered his opening message: the Fed's mission is price stability and maximum employment, and he intends to run an independent, reform-minded institution.

What's really interesting is the subtext here. Warsh has a history. He served as a Fed governor during the 2008 global financial crisis and was actually critical of the second round of quantitative easing back in 2011 — so critical that he eventually left the institution. Markets don't see him as a simple dove who will rush to cut rates. At the same time, he has recently signaled openness to the idea that advances in AI and productivity gains could allow economic growth without triggering inflation. That's a more nuanced view than a straight hawk or dove label would suggest.

The Korean Economic Challenge

For Korea, this creates a tricky situation no matter which way Warsh leans. If U.S. interest rates stay high, the dollar stays strong, which pushes up the value of the won-dollar exchange rate. That can give Korean exporters a short-term boost, but it also makes energy and raw material imports more expensive, driving up inflation at home. And a strong dollar makes U.S. assets more attractive to global investors, potentially pulling foreign capital away from Korean markets — something Korea can ill afford, especially with Middle East tensions adding pressure to oil prices at the same time.

The broader point made by Korean economists is that this is not just about watching the Fed's next move. Korea needs to build its own buffers — managing foreign exchange liquidity, keeping a close eye on dollar-denominated corporate debt, and most importantly, strengthening the competitiveness of its own industries in AI, semiconductors, batteries, and shipbuilding. The strongest defense against currency volatility, the argument goes, is a productive and competitive economy that doesn't need to lean on external monetary conditions.

There's also a pointed reminder about central bank independence closer to home. The Bank of Korea, Korea's own central bank, faces similar pressures to align rate decisions with political cycles or public opinion. Analysts warn that if monetary policy becomes a tool of short-term political management, credibility is the first casualty — and with it, the ability to stabilize the currency and prices.

Samsung's Housing Loan Perk and the Fairness Question

Now for the story that's generating the most heated debate inside Korea this week. And it cuts right to the heart of economic fairness. While the government talks tough on real estate speculation, a new labor agreement at Samsung Electronics — one of Korea's largest and most powerful companies — reportedly includes an in-house housing loan benefit that many ordinary Koreans simply cannot access.

Here's the deal: according to reports on the tentative wage agreement between Samsung Electronics and its union — a deal that still needs to go through a membership vote — employees without a home of their own could borrow up to 500 million won, about 360,000 dollars, to purchase a house, or up to 300 million won for a lease deposit, at an interest rate of just 1.5 percent per year, with up to ten years to repay. For comparison, commercial bank mortgage rates in Korea are currently far higher than that.

The Regulation Gap That Has People Talking

So here's the thing that's making this controversial. The Korean government has been tightening mortgage regulations — through what are called DSR (Debt Service Ratio) and LTV (Loan-to-Value) limits — specifically to cool the housing market and manage household debt. These rules cap how much an ordinary citizen can borrow from a bank to buy a home. But in-house corporate loans, funded through employee welfare funds, sit outside these regulatory frameworks entirely. They don't count toward DSR or LTV calculations.

That means a Samsung employee could potentially access hundreds of millions of won in housing finance on top of whatever they can borrow from a bank, without either loan counting against the other in regulatory terms. Critics argue this creates a two-tiered housing market where large corporation employees and ordinary citizens are playing by fundamentally different rules — in the same property market.

Samsung is far from alone. SK Hynix reportedly offers up to 100 million won at 1.5 percent interest. SK Telecom offers a similar amount at 1.2 percent. Hyundai Motor reportedly has loans of up to 100 million won at around 2 percent. Crypto exchange operator Dunamu reportedly raised its in-house loan limit from 300 million to 500 million won in 2025 — interest-free — even as the government was tightening public lending rules.

And then there's the issue of public institutions. Korea's central bank, the Bank of Korea, along with major policy finance bodies like the Korea Land and Housing Corporation, the Korea Housing Finance Corporation, and the Korea Development Bank, reportedly also offer in-house housing loan benefits to their own employees. These are the very institutions tasked with managing household debt, setting housing policy, and maintaining financial stability. The optics of that, commentators note, are difficult to defend.

A Structural Problem, Not Just a Corporate One

Seoul apartment prices rose for the 66th consecutive week as of the second week of May, according to the Korea Real Estate Board, with prices up 0.28 percent from the previous week. In that environment, the gap between those who can access cheap capital and those who cannot translates directly into a gap in who can actually buy a home.

Critics are not calling for Samsung to take away its employees' benefits. The point being raised is about equity and policy consistency. Workers at small and medium-sized companies, freelancers, and self-employed individuals face the full weight of lending restrictions while competing in the same housing market against people who have access to large, low-interest loans that regulators cannot see. That, analysts say, is a structural problem the government needs to address — not by pulling corporate welfare down, but by extending meaningful housing finance support to those currently left out of the system entirely.

As the old Confucian saying goes — and it is quoted in the original Korean commentary on this story — "Without stable livelihood, there can be no stable heart." Right now, a lot of Koreans are finding it very hard to feel stable about where they live.

This article is based on reports from Seoul Economic Daily, Ajunews, Cfnews.